Mr. Hugh MacNaught reports

VENTRIPOINT ISSUE SHARES FOR PAYMENT OF DEBENTURE INTEREST

Ventripoint Diagnostics Ltd. will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange approval. The corporation will issue an aggregate of 555,699 common shares for the payment of an aggregate of $61,217 of interest owing on certain outstanding convertible debentures issued by the corporation on Sept. 20, 2024, March 21, 2025, Sept. 2, 2025, and Oct. 14, 2025. The convertible debentures bear interest at the rate of 10 per cent per annum, payable every six months. The shares will be issued at a deemed price of 11 cents, subject to the approval of TSX-V, and are subject to a hold period of four months and one day. The issuance of the shares will not create a control person of the corporation.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's' future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.